Transforming Hemophilia Care: A New Generation of Extended Half-Life Factor Concentrates

New extended half-life products represent a powerful new tool for improving the care and quality of life for persons with hemophilia.
Using Genomic Data to Personalize Cancer Treatment

Researchers are using genomics research to better understand how genetic variation contributes to human health and disease.
The New Therapeutic Renaissance for Patients with Rare Bleeding Disorders

As it has since the first commercially produced factor VIII concentrate transformed the lives of U.S. hemophilia A patients, innovation is still the life-blood of this industry.
BabyBIG: Definitive Early Immunotherapy for Infant Botulism

Explore the history and trace the development of BabyBIG, the life-saving immunotherapy for infant botulism.
Precision Medicine: A Seismic Shift in Treatment Strategy

Still in its infancy, precision medicine holds out hope for moving directly from diagnosis to an effective tailor-fit treatment for each individual patient.
The Future Has Arrived: A Wave of New Products Is Redefining Hemophilia Care

New long-acting therapeutics are changing the way hemophilia is managed, creating more choice and better treatment compliance.
Grifols Invests in Alkahest to Develop Plasma-Based Products

Grifols has made a major equity investment in Alkahest to work together to develop novel plasma-based products for the treatment of cognitive decline in aging and disorders of the central nervous system.
Severe PIs: Cutting-Edge Science Turns Tragedies to Cures

For decades, donor blood stem cell transplantation has been the only potential cure for severe primary immunodeficiency disorders, but it has been limited by failure and serious complication risks. Now, a trifecta of scientific advances is transforming the prognosis for children once defenseless against life-threatening infections.
Game On! The Age of Gamification

Healthcare industry stakeholders are increasingly using diagnosis-specific apps and educational gaming platforms to engage with patients, encourage compliance and even manage treatment options.
Long-Acting Factor Concentrates: The Next Leap Forward in Hemophilia Care Arrives

Treatment advances over the past 40 years have transformed the lives of people with hemophilia, and more innovation lies ahead.